REBIF
REBIF is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis in adult patients. The medication is used to manage various stages of the disease, including clinically isolated syndrome and relapsing-remitting disease. It is also approved for the treatment of active secondary progressive disease. As a therapeutic agent in the interferon beta class, it is used to address the relapsing manifestations of multiple sclerosis.
How REBIF Works
REBIF is a pharmaceutical product belonging to the interferon beta class. The exact biological mechanism by which interferon beta-1a produces its therapeutic effects in patients with multiple sclerosis is currently unknown. While the drug is used to treat relapsing forms of the disease, the specific pathways and targets involved in its clinical activity have not been identified.
Details
- Status
- Prescription
- First Approved
- 2002-03-07
- Routes
- N/A
- Dosage Forms
- SYRINGE
REBIF Approval History
What REBIF Treats
1 indicationsREBIF is approved for 1 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Multiple Sclerosis
Drugs Similar to REBIF
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
REBIF FDA Label Details
ProIndications & Usage
FDA Label (PDF)REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.